Merck’s blockbuster cancer immunotherapy Keytruda just delivered its first $8 billion quarter, but the pharmaceutical giant faces a critical deadline. With patent protection expiring in 2028, the company is racing to cut costs and diversify beyond its flagship product.
Scientists have engineered advanced nanogel systems that effectively encapsulate and protect negatively charged therapeutic molecules. The breakthrough technology demonstrates significant potential for improving delivery of challenging biopharmaceuticals like nucleic acid-based drugs while maintaining excellent biocompatibility.
Researchers have developed a groundbreaking peptide-based nanogel system that shows remarkable potential for delivering negatively charged therapeutic molecules, according to recent scientific reports. The technology addresses a significant challenge in pharmaceutical science: effectively encapsulating and protecting anionic bioactive compounds that have traditionally been difficult to administer.
The Endometriosis Diagnostic Revolution For decades, endometriosis diagnosis has relied on invasive laparoscopic surgery, creating significant barriers to timely treatment.…
The New Healthcare Revolution: From Hospital Beds to Legislative Halls Across America, a quiet revolution is transforming how healthcare decisions…
Africa’s First Supercritical CO₂ Facility Marks Manufacturing Revolution The Council for Scientific and Industrial Research (CSIR) has launched Africa’s inaugural…
University of Pennsylvania scientists have discovered a specific group of neurons that could serve as an off switch for chronic pain. The research reveals how activating these Y1R neurons may provide lasting relief for conditions like arthritis and fibromyalgia.
Scientists may have discovered the potential off button for chronic pain through groundbreaking research on specific brain neurons. University of Pennsylvania biologist Nicholas Betley and his team identified that activating Y1R neurons in the parabrachial nucleus could provide lasting relief for millions suffering from persistent pain conditions. This discovery opens new pathways for developing targeted medications that could fundamentally change how we treat chronic pain disorders.
